HomeBiosimilar Antibodies

Biosimilar Antibodies

Cat.No. Product Name Information Isotype
A2786 Anti-BACE1 (Genentech anti-BACE1) Anti-BACE1 (Genentech anti-BACE1) is a monoclonal anti-BACE1 antibody (mAb) that reduces endogenous BACE1 activity and amyloid-β (Aβ) production. It has the potential to treat Alzheimer's disease. MW: 144.22 KD. Human IgG1
A3042 Revdofilimab (Anti-TNFRSF4 / OX40 / CD134) Revdofilimab (Anti-TNFRSF4 / OX40 / CD134) is a human IgG1 agonist monoclonal antibody targeting OX40. It has antitumor activity and can be used in research of advanced solid tumors. MW :145.54 KD. Human IgG1
A2787 Blosozumab (Anti-SOST / Sclerostin) Blosozumab (anti-SOST/ Sclerostin) is a humanized monoclonal antibody against sclerostin. Blosozumab stimulates bone formation, reduces bone resorption, and has the potential to be used in the research of osteoporosis. MW: 144.88 kD. Human IgG4SP
A3043 Anti-PDGFRB / CD140b (IMC-2C5) Anti-PDGFRB / CD140b (IMC-2C5) is a fully human antagonistic antibody targeting PDGFRβ It enhances antitumor activity and antiangiogenic agents in the treatment of a broad range of human cancers. MW :145.06 KD. Human IgG1
A2788 Bococizumab (Anti-PCSK9) Bococizumab (Anti-PCSK9) is a humanized monoclonal IgG2Δa antibody against proprotein convertase subtilisin/kexin type 9 (PCSK9) used for the treatment of hyperlipidemia. MW: 145.06 kD. Human IgG2SA
A3044 Robatumumab (Anti-IGF1R / CD221) Robatumumab (Anti-IGF1R / CD221) is an antibody targeting human IGF-1R (insulin-like growth factor receptor-1). It shows anti-tumor activity and anti-proliferative activity to cancer cells and can be used in osteosarcoma and Ewing sarcoma research. MW :144.6 KD Human IgG1
A2789 Anti-PCSK9 (Boehringer anti-PCSK9) Anti-PCSK9 (Boehringer anti-PCSK9) is a monoclonal antibody against proprotein convertase subtilisin/kexin type 9 (PCSK9) that prevents PCSK9-mediated degradation of the LDLR.MW: 146.42 kD. Human IgG1
A2790 Eptinezumab (Anti-CALCA / CGRP) Eptinezumab (Anti-CALCA / CGRP) is a humanized monoclonal antibody that binds to calcitonin gene-related peptide (CGRP) and blocks its binding to the receptor. It is used in the preventive treatment of episodic migraine. MW: 143.36 kD. Human IgG1
A3046 Anti-CYR61 / CCN1 Anti-CYR61 / CCN1 is a monoclonal antibody targeting cysteine-rich protein 61(CCN1/Cyr61) . It can be used in breast cancer treatment. MW :144.42 KD. Human IgG1
A2791 Fremanezumab (Anti-CALCA / CGRP) Fremanezumab (Anti-CALCA / CGRP) is a humanized IgG2a monoclonal antibody that selectively and potently targets calcitonin gene-related peptide (CGRP). Fremanezumab has the potential for chronic migraine research.. MW: 145.5 kD. Human IgG2SA
A3047 Anti-PRLR / Prolactin Receptor Anti-PRLR / Prolactin Receptor is a potent monoclonal antibody, targeting prolactin (PRL) receptor. It is considered a good candidate for further development in endometriosis or other PRL-mediated disease conditions. MW :143.8 KD Human IgG1
A2792 Anti-ABCB5 Anti-ABCB5 is a monoclonal antibody (mAb) against ABCB5 (ATP-binding cassette transporter, sub-family B (MDR/TAP), member 5) with the potential to be used in research on melanoma. MW: 147.74 KD. Human IgG1
A2793 Anti-CD151 Anti-CD151 is an anti-CD151 monoclonal antibody (mAb) with potential anti-metastatic and anti-tumor activity activity. MW: 146.76 KD. Human IgG1
A3049 Anti-RAMP3 Anti-RAMP3 is a polyclonal antibody targeting RAMP2. It is useful in the treatment of cancer. MW :147.04 KD. Human IgG1
A2794 Anti-EMMPRIN / CD147 Anti-EMMPRIN / CD147 is a monoclonal antibody against extracellular matrix metalloproteinase inducer (EMMPRIN; CD147) with potential anti-proliferative activity. MW: 145.42 KD. Human IgG1
A3050 Anti-RHD / CD240d (LFB Anti-RhD) Anti-RHD / CD240d (LFB Anti-RhD) is a polyclonal IgG antibody specificly targeting RhD (rhesus D). It is used in the treatment of fetal hemolytic disease. MW :147.46 KD. Human IgG1
A2795 Denintuzumab (Anti-CD19) Denintuzumab (anti-CD19) is a recombinant humanized anti-CD19 monoclonal antibody that can be used in the research of acute lymphoblastic leukemia. Denintuzumab can be used to synthesize ADC antibody Denintuzumab Mafodotin (SGN-CD19A). MW: 145.0 kD. Human IgG1
A3051 Atinumab (Anti-RTN4 / NOGO) Atinumab (Anti-RTN4 / NOGO) is a monoclonal antibody targeting reticulon-4. It has immunomodulating activity and can be used for the research of spinal cord injury (SCI). MW :137.82 KD. Human IgG4SP
A3052 Anti-S100A4 (LK-1) Anti-S100A4 (LK-1) is a monoclonal antibody targeting the small Ca-binding protein, S100A4. It can be used in development of an efficient anti-metastatic therapy in various cancers. MW :145.04 KD. Human IgG1
A2797 Anti-IL-25 Anti-IL-25 is a humanised monoclonal antibody against Interleukin-25 (IL-25) with the potential to treat airway hyperresponsiveness (AHR). MW: 146.02 KD. Human IgG1